Viracta Therapeutics Is Maintained at Outperform by RBC Capital

Dow Jones11/15 01:18

RBC Cuts Price Target on Viracta Therapeutics to $2 From $4, Keeps Outperform, Speculative Risk

MT Newswires11/14 20:40

サネシス・ファーマシューティカルズ | 10-Q：Q3 2024 四半期報告書

SEC11/14 05:36

Press Release: Viracta Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

Dow Jones11/13 20:00

Viracta Therapeutics: Expect to Recognize About $700,000 in Total Expenses for Severance and Related Benefits >VIRX

Dow Jones11/07 05:45

Viracta Therapeutics: Implementing 42% Reduction in Force and Resizing Bd of Directors to Six Seats From Ten >VIRX

Dow Jones11/07 05:44